PORTOLA VALLEY, CA, August 5, 2021 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data showing that herbal medicines have potent activity in test tubes compared to pharmaceuticals commonly-prescribed for the treatment of Bartonella henselae, a bacterium believed to be carried by ticks and the cause of cat scratch fever. This is the first study to find antimicrobial activity of some of these herbal medicines. Published in the journal Infectious Microbes & Diseases, the laboratory study was funded in part by the Bay Area Lyme Foundation.
“With increasing rates of tick-borne diseases and a consistent concern about the overuse of antibiotics, this early research of herbals is extremely exciting,” said Linda Giampa, executive director, Bay Area Lyme Foundation. “We are hopeful that future pre-clinical and clinical studies will continue to show that herbals have the same effectiveness as this study and other recently-published studies.”
The study is the first to demonstrate that these three herbal medicines had high activity against stationary phase Bartonella henselae:
- Black walnut (Juglans nigra)
- Cryptolepis (Cryptolepis sanguinolent)
- Japanese knotweed (Polygonum cuspidatum)
The study also confirmed the anti-microbial activity of these two herbal medicines against the same bacteria:
- Barbat skullcap (Scutellaria barbata)
- Chinese skullcap (Scutellaria baicalensis)
Three of these – Chinese skullcap, Cryptolepis, and Japanese knotweed – have previously been shown, in similar test tube models, to also be effective against both Borrelia burgdorferi, the bacteria that causes Lyme disease, and Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis. These three herbal medicines, as well as black walnut, were shown to be more effective than commonly prescribed antibiotics against Borrelia burgdorferi.
“As many people with Lyme disease are co-infected with other pathogens, these findings, which show that certain herbal medications are effective in the lab against multiple tick-borne infections, are an important advance for the tick-borne disease community,” said co-author Sunjya K. Schweig, MD, Founder and Director, California Center for Functional Medicine and Scientific Advisory Board Member, Bay Area Lyme Foundation. Collaborating researchers were from Johns Hopkins Bloomberg School of Public Health, California Center for Functional Medicine, FOCUS Health Group, Naturopathic, and Zhejiang University School of Medicine.
“Because so many patients with tick-borne disease do not respond to the standard treatments outlined in medical guidelines, we need research on potential alternatives that can fill this gap and aid in the recovery of patients managing acute and long-term symptoms,” added Dr. Schweig.
Two commonly prescribed antibiotics for tick-borne infections, doxycycline and azithromycin, cleared the persistent form of the bacteria at approximately the same levels as the drug-free control. Comparisons of the pharmaceuticals daptomycin and methylene blue had better activity against stationary phase B. henselae (residual viability of the bacteria reduced to below 40%) than gentamicin, rifampin, and miconazole, which showed relatively better activity (residual viability of the bacteria reduced to below 50%) against stationary phase B. henselae than doxycycline, and azithromycin (residual viability of the bacteria reduced only to 66% and 70% respectively).
These botanical compounds still need to be tested in animal models as well as in clinical trials. While each of these botanical medicines are already in clinical use, it is important for future studies to evaluate them directly in patients using specific clinical treatment regimens, as each have the potential to produce side effects in patients, and should be taken only under the care of a clinician knowledgeable of their capabilities, interactions and toxicities.
About the Study
The paper titled “Botanical Medicines with Activity Against Stationary Phase Bartonella henselae,” was authored by Xiao Ma, Jacob Leone, ND, Sunjya Schweig, MD, and Ying Zhang, MD, PhD.
Plant extracts selected for the study included botanical medicines that have been previously used to manage the symptoms of patients who do not respond to standard pharmaceutical treatments and have favorable safety profiles. For primary screens, all the herbal products were applied at two concentrations, 1% (v/v) and 0.5% (v/v), respectively.
Study authors utilized a similar rapid high-throughput drug screening method, a SYBR Green I/ propidium iodide (PI) viability assay, as previous studies evaluating herbal medicines against stationary phase B. burgdorferi and B. henselae.
These data suggest that it may be advantageous to use these herbal medicines to simultaneously target multiple different pathogens in patients with complex Lyme disease with coinfections. The data also may also provide encouragement for future studies for patients, particularly those whose chronic symptoms may be due to persistent bacteria that are not killed by conventional antibiotic treatment. However, it is critical to note that additional studies are needed to further evaluate the active botanical medicines identified in the study. Patients should not attempt to self-treat with these herbal medicines due to potential side effects and lack of clinical trials with these products.
Bartonellosis is a collection of emerging infectious diseases, including cat scratch disease, trench fever, Carrion’s disease, and bacillary angiomatosis. Bartonellosis is caused by the Bartonella family of bacteria, which can be transmitted via ticks, fleas, lice and sandflies. Symptoms may include fever, lymphadenopathy, malaise, abdominal pain, endocarditis and arthritis, and serious complications can develop in patients for whom the disease progresses, including seizures, cranial nerve palsies, and aseptic meningitis, as well as enlargement of the heart, liver and/or spleen, among other symptoms. There is no single treatment effective for Bartonella-associated diseases, and antibiotic recommendations differ depending on specific presentations.
About Bay Area Lyme Foundation
Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is a leading public charity sponsor of innovative Lyme disease research in the US. A 501c3 non-profit organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM Fund covers overhead costs and allows for 100% of all donor contributions to Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit http://www.bayarealyme.org or call us at 650-530-2439.
# # #
Infectious Microbes & Diseases
Botanical Medicines with Activity Against Stationary Phase Bartonella henselae
ARTICLE PUBLICATION DATE
Categories: All Posts